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ABSTRACT
The use of RNA macromolecules as therapeutic agents for HIV and other infectious diseases is promising but limited by
suboptimal delivery to the target site. With HIV infection, this is particularly challenging since lymphocytes are particularly
difficult to transfect. This paper describes an innovative strategy for the intracellular delivery of a novel single-stranded RNA
(oligoribonucleotide) with putative anti-HIV activity. This strategy is based on a PEGylated gold nanoparticle scaffold covalently
linked to the thiol-modified oligoribonucleotide via a cleavable N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) linker
molecule. The nanoparticle was then coated with a cationic polymer (polyethyleneimine) to facilitate cell entry and endosomal
escape. A synthetic anti-CD4 cyclic targeting peptide was attached to the polyethyleneimine-coated nanoparticle via an SPDP
linker molecule, in an attempt to enhance uptake and selectivity. Synthesis, characterization, SPDP and RNA loading,
cytotoxicity and antiviral activity of the nanoparticle are described. Approximately 45 000 strands of RNA were taken up per
lymphocyte. Uptake was limited by relatively inefficient loading of RNA onto the gold nanoparticle surface (1 strand per 4.8 nm2
of nanoparticle surface area) and significant aggregation of the nanoparticle in physiological solutions. No antiviral activity was
demonstrated, possibly due to insufficient intracytoplasmic delivery of the RNA.
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1. Introduction
Various strategies exist for the use of RNA macromolecules as
therapeutic agents for HIV and other infectious and non-
infectious diseases. These strategies include RNA interfer-
ence (RNAi), ribozymes, aptamers, siRNA, microRNAs, anti-
sense oligonucleotides and steric-blocking oligonucleotides.1–3
However, the major impediment to RNA therapeutics is ineffi-
cient or unreliable delivery4 i.e. the safe passage of non-
sequestered RNA, via the cell membrane, to its target site in the
cytoplasm (or nucleus), at sufficient concentration, and for long
enough, so as to exert the desired effect.5–6 The challenges with
efficient delivery of nucleic acids include their short half-life in
plasma,4–5,7–9 excretion by the kidneys, entrapment by the
reticuloendothelial system,8 formation of aggregates with serum
proteins,10 inability to cross biological membranes (including
the cell membrane) because of strong negative charge10, and
entrapment within vesicles within the cytoplasm.5,8 Lympho-
cytes, in particular, are difficult to transfect,11 which significantly
limits the potential of RNA therapeutics for the treatment of HIV
infection.
In an attempt to address these challenges, numerous methods
have been developed for RNA delivery including viral vector
based strategies, direct delivery by physical methods, chemical
methods and nanotechnology approaches. However, finding a
safe and effective method to achieve systemic and targeted
delivery of RNA has remained an elusive goal,12–13 and siRNA
delivery has only recently entered clinical trials.13
This paper describes the synthesis, characterization and bio-
logical interaction of a multifunctional nanoparticle construct
which attempts to address some of these challenges. The con-
struct is based on the following facets (Fig. 1):
1. A gold nanoparticle scaffold to provide structural support
Assembly onto a gold nanoparticle scaffold facilitates
orderly interaction between RNA, polyethyleneglycol
(PEG) and polyethyleneimine.14–15 A similar system, based on
inorganic gold particles and biodegradable polycations, has
proven to be successful in safely and effectively delivering
DNA,16–17 and more recently RNA, into cells.15 Gold nano-
particles are desirable nanocarriers because they are chemi-
cally stable and inert, biocompatible, have low cytotoxicity,
can be synthesized in varying sizes with limited dispersity,
have unique surface properties which allow for dense
loading of multiple ligands, are amenable to multi-
functionalization and have unique optical properties (that
allow characterization and quantification).14–15,18–25 Further-
more, gold nanoparticles enhance the transfection efficiency
of polyethyleneimine.26
2. PEG polymer to enhance biocompatibility
PEGylation reduces aggregation and non-specific interac-
tions of gold nanoparticles with plasma proteins (i.e. pro-
motes ‘stealth’ behaviour) and furthermore enhances their
solubility, circulation time in the bloodstream,27 cytotoxicity
profile and stability in physiological solutions.28–29 Insertion of
a PEG ‘spacer’ molecule between the gold surface and the
RNA also prevents reaction of the nanoparticle with the
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disulphide bond between the RNA and the linker molecule.15
3. A cleavable linker molecule (N-succinimidyl 3-(2-pyridyldithio)
propionate or SPDP) to allow conjugation and release of the RNA
The thiol modified RNA was conjugated to the gold
nanoparticle via a disulphide bond using the linker molecule
SPDP. The disulphide bond is stable in the ionic, extracellular
environment but is cleaved in the reductive conditions
within the cytoplasm (thus releasing the RNA from the
nanoparticle).15 More specifically, the disulphide bond is
cleaved by intracellular glutathione, which is found in much
higher concentration in intracellular vs. extracellular environ-
ments and this facilitates the selective intracellular release of
the RNA.30
4. A single-stranded RNA molecule designed to inhibit
HIV packaging
The sequence of the 16-mer single-stranded RNA is based
on the packaging signal of HIV-1. It is designed to inhibit the
encapsidation of the HIV genome by a decoy mechanism.31
5. Polyethyleneimine to enhance cell entry and facilitate endosomal
escape
Polyethyleneimine, a synthetic cationic polymer, is the pro-
totype non-viral gene delivery system and a popular choice
for RNA transfection, since it protects RNA from enzymatic
degradation, enhances cell entry and facilitates endosomal
escape.32 Polyethyleneimine facilitates interaction between
RNA and the cell membrane (both of which are negatively
charged). Once the nanoparticle is taken up by endocytosis,
polyethyleneimine facilitates release from the endosome via
the ‘proton sponge’ effect.33–44 Polyethyleneimine then
decondenses and separates from the nanoparticle, thus
allowing release of the RNA.39,45 However, its use is somewhat
limited by toxicity (probably due to unstable complexes in
serum, resulting in release of unbound polyethyleneimine).32
Gold nanoparticles, by comparison, are far less toxic, but their
use as transfection agents is hampered by endosomal entrap-
ment and inefficient release of its nucleic acid cargo into the
cytoplasm (due to high binding affinity between RNA and
the surface of gold nanoparticles).46 Several studies have
therefore sought to conjugate polyethyleneimine to gold
nanoparticles in order to overcome the disadvantages of
each i.e. to attenuate the toxicity of polyethyleneimine, and
to enhance intracellular release of GNP systems.42,46–50 Addi-
tionally, polyethyleneimine has been successfully ‘tagged’
with peptides to further enhance transfection efficiency and
to facilitate targeted delivery.51–55 Also, an experimental
layer-by-layer electrostatic approach has been used to over-
come aggregation issues42. We therefore postulated that the
use of polyethyleneimine-coated GNP may overcome the
barrier to successful delivery of RNA to the cytoplasm of
hard-to-transfect lymphocytes.
6. Peptide functionalization
A synthetic cyclic peptide, designed to target the CD4
receptor, was attached to the surface of the gold nanoparticle
via an SPDP linker molecule that facilitated conjugation to the
branched polyethyleneimine.56 The design of the peptide was
based on the amino acid sequence of an anti-CD4 monoclonal
antibody. In previous studies, the peptide was found to bind
to the CD4 receptor and furthermore inhibit cellular func-
tions that depend on this receptor.57–61 In this paper, it is
hypothesized that the presence of a targeting ligand on the
surface of the gold nanoparticle would facilitate its selective
uptake by CD4 lymphocytes via a receptor-mediated endo-
cytosis pathway.
2. Materials and Methods
2.1. Reagents
All chemicals and reagents were obtained from Sigma–Aldrich
(St. Louis, Missouri, USA), unless otherwise stated. Thiol-(PEG)-
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Figure 1 Schematic representation of multifunctional, PEGylated gold nanoparticle construct, showing RNA with putative anti-HIV activity, at-
tached via an SPDP linker. The particle was coated with polyethyleneimine and bears a cyclic anti-CD4 peptide on the surface. The attachment of the
SPDP linker to the thiol-PEG-amine and RNA is shown in more detail on the right. Portion of this figure are based on Lee et al.15
amine (HSCH2CH2O(CH2CH20)nCH2CH2NH2, MW = 1KDa) was
obtained from Layson Bio (Arab, Alabama, USA). RNAse-free,
HPLC-purified 5’ thiol modified, 3’ fluorescein labelled RNA
was custom synthesized by Dharmacon (Pittsburgh, Pennsylva-
nia, USA). RNAsecure Reagent and RPMI 1640 medium was
obtained from Life Technologies (Grand Island, New York,
USA). Heat-inactivated fetal calf serum was obtained from
Biochrom GmbH, Berlin, Germany). The MT4 lymphocyte cell
line was obtained from the NIH AIDS Reagent Program, Divi-
sion of AIDS, NIAID, NIH, courtesy of Dr Douglas Richman.
Virus stock (HIV-1 IIIB) was obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH: HTLV-IIIB/H9
from Dr Robert Gallo.62–64
2.2. Synthesis
2.2.1. Synthesis of Gold Nanoparticle
Gold nanoparticles (diameter 30–40 nm) were synthesized
using the well-described method of Turkevich, in which
chloroauric acid (HAuCl4.3H2O) is reduced by trisodium citrate
(Na3C6H5O7.2H2O).
65,68 Briefly, 500 mL of a 1 mM solution of
chloroauric acid in double-distilled water was mechanically
stirred and brought to a vigorous boil under reflux. Then 50 mL
of 19.5 mM trisodium citrate was rapidly added to the boiling
solution. The colour of the solution changed from dark purple to
wine red and the reaction was continued for a further 15 min.
The solution was allowed to cool to room temperature and
stored at 4 °C. All glassware was thoroughly washed with aqua
regia, rinsed with double-distilled water and oven-dried over-
night prior to use. The size and concentration of the gold
nanoparticles was determined by UV-vis spectrophotometry
using the method of Haiss.69 The concentration of the gold
nanoparticle solution was adjusted to ~30 nM and stored at
2–8 °C until use.
2.2.2. PEGylation of Gold Nanoparticle
The heterobifunctional polymer thiol-PEG-amine contains a
thiol group that reacts readily with the citrate-capped surface of
the gold nanoparticle, and an amine group that attaches to
N-hydroxysuccinimide ester of the SPDP linker in the next step.
The thiol-PEG-amine was reacted with the gold nanoparticle
using the same number of moles of PEG per nm2 surface area of
gold nanoparticle as Anderson’s group.15 In a typical reaction,
32 mg of thiol-PEG-amine was added to 100 mL gold
nanoparticle solution (~0.5 nM) and incubated at 25 °C for 12 h
with constant mechanical stirring. Tween-20™ at a concentra-
tion of 0.01 % (v/v) was added to the solution at the beginning of
the reaction to prevent adherence of the nanoparticles to the
surface of the reaction vessel. The particles were washed four
times by centrifugation at approximately 20 000 × g, followed by
removal of the supernatant and re-dispersion in PBS containing
0.01 % Tween-20™. Re-dispersion was aided by vortexing and
bath sonication for approximately 10 s each. The absence of
aggregates was confirmed by visual inspection and by light
microscopy. Successful PEGylation was confirmed by the colloi-
dal stability test.70 Briefly, bare gold nanoparticles aggregate and
form a purplish solution, while PEGylated nanoparticles retain
their wine red colour when exposed to highly saline conditions
(10x phosphate buffered saline). Furthermore, PEGylated gold
nanoparticles migrate differently compared to bare gold
nanoparticles on gel electrophoresis, due to loss of surface
charge upon PEGylation. See Supplementary Material (Appen-
dix A) for further details on the colloidal stability test and gel
electrophoresis. The size and concentration of the NH2-PEG-
gold nanoparticles was determined by UV-vis spectrophoto-
metry.15,69 The solution was stored at 4oC until ready for use.
2.2.3. Addition of the Linker Molecule (SPDP) to PEGylated Gold
Nanoparticle
SPDP was reacted with the PEGylated gold nanoparticle solu-
tion using the same number of moles of SPDP per nm2 surface
area of gold nanoparticle as Anderson’s group.15 In a typical reac-
tion, 500 µL SPDP in PBS (3 mM, solubilized with 10 % DMSO)
was incubated for 40 min with 500 µL NH2-PEG-AuNPs in PBS
(2.7 nM, with 0.01 % T Tween-20™, pH 7.4) at 25 °C with vigorous
vortexing. The unconjugated SPDP was removed by repeated
centrifugation and re-dispersion as described for the PEGylation
reaction above.
2.2.4. RNA Conjugation
In this step, the 5’thiol of the RNA reacts with the 2-pyridylthio
group of SPDP.15 The RNAse-free, HPLC-purified 5’ thiol modi-
fied, 3’ fluorescein labelled RNA construct (Dharmacon, Pitts-
burgh Pennsylvania, USA) was reduced71 and de-protected72 as
recommended by the manufacturer. The sample was dried using
a centrifugal evaporator (miVac DNA Sample Concentrator,
Genevac, Stone Ridge, New York, USA) and re-suspended in
Borate Buffered Saline (BBS) with 0.01 % Tween-20™ (pH
8.3–8.5). The BBS was incubated with RNAsecure Reagent (Life
Technologies, Grand Island, New York, USA) for 10 min at 60 °C,
to remove potential RNAses prior to use. The RNA was quanti-
fied by obtaining an absorbance at 260 nm. The software
provided by the manufacturer allows an adjustment to be made
to account for the effect of fluorescein on the absorbance reading
(BioSpec Nano, Shimadzu Corporation, Kyoto, Japan). The
SPDP-NH2-PEG-gold nanoparticle was re-suspended in 2 mL
borate buffered saline containing the RNA (15 µM RNA, 2.5 M
NaCl solution, 30 mM borate, pH 8.5, 0.01 % Tween-20™) and
incubated at 25 °C for 40 h with vigorous vortexing. The particles
were then washed four times by centrifugation at 15 700 × g for
15 min42 at 4 °C73, removal of the supernatant and re-dispersion
in sterile phosphate buffered saline (137 mM NaCl solution,
10 mM phosphate, 2.7 mM KCl, pH 7.4, 0.01 % Tween-20™).
In the final wash, the nanoparticle solution was adjusted to a
concentration of 2 µM and re-suspended in 10 mM NaCl solu-
tion. Re-dispersion was aided by vortexing and bath sonication
for approximately 10 s each. The RNA was protected from light.
2.2.5. Polyethyleneimine Coating
In this step, branched polyethyleneimine with an average
molecular weight of 25 KDa was added at a final concentration of
1.0 mg mL–1 to a stirring solution of RNA-gold nanoparticles in
10 mM NaCl solution. This was then incubated at room tempera-
ture for 30 min, in order to form a polyelectrolyte layer around
the outer surface of the gold nanoparticle. The nanoparticles
were then washed by centrifugation and re-dispersion in 10 mM
NaCl solution.42
2.2.6. Peptide Conjugation
A targeting peptide was attached to the surface of the gold
nanoparticle. The sequence of the peptide was derived from the
variable domains of an anti-CD4 monoclonal antibody and has
been previously published.57–61 The peptide was synthesized by
routine FMoc (9-fluorenylmethoxycarbonyl) Solid Phase Syn-
thesis74–78 on a CEM microwave peptide synthesizer79–80 and
cyclized by on-resin iodine-oxidation of cysteine residues close
to the N and C termini of the peptide.60,81 An AAC ‘tail’ at the end
of the peptide facilitated conjugation to the polyethyleneimine
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via an SPDP linker molecule.56 See Supplementary Material (Ap-
pendix B) for further details of the peptide and its synthesis.
2.3. Characterization
2.3.1. Size, Polydispersity, Zeta-potential and Concentration
Size, polydispersity, zeta-potential and concentration of the
nanoparticles were determined at the end of each step of the
synthesis process. The size and concentration of the gold
nanoparticles was determined by UV-vis spectrophotometry
using the method of Haiss.69 The hydrodynamic diameter,
zeta-potential and polydispersity were determined using
the Malvern Zetasizer (Malvern Instruments, Worcestershire,
United Kingdom). A general-purpose analysis model was
selected for size measurements. The angle of detection was 175 °.
For zeta potential measurements, the Smoluchowski F(ka) value
of 1.5 was used for the Henry’s equation. For both size and zeta
potential, the automatic setting was selected to allow the soft-
ware to determine the optimal duration of measurement.
2.3.2. Visualization of Nanoparticles by Electron Microscopy
For visualization of gold nanoparticles, a drop of the solution
was placed on a copper grid and allowed to dry and then visual-
ized on a JEOL 2100 High Resolution Transmission Electron
Microscope.82 A representative image was imported into Image J
and transformed into a monochrome 8-bit format. The scale of
the image was set and the ‘brightness’ threshold adjusted appro-
priately. The mean, range and standard deviation of the diame-
ter of at least 30 particles was determined using a manual particle
sizing method.83
2.3.3. Aggregation
To study the factors associated with aggregation of poly-
ethyleneimine-coated nanoparticles, the final product was spun
down and re-suspended in solutions adjusted to a range of
pH values and with FBS (at varying percentages 0, 5, 10 and
20 %) and Tween-20™. Aggregation was quantified visually by
dispensing the aliquots of the various nanoparticle solutions
into the well of a clear flat-bottomed microtitre plate, which were
then viewed under a Leica DMIL light microscope (Leica,
Wetzlar, Germany) at ×200 magnification. Images were cap-
tured on a Zeiss Axiocam 105 camera (Carl Zeiss, Oberkochen,
Germany). The images were imported into Image J software in
an 8-bit grayscale format, and the black: white threshold was
adjusted by the maximum entropy method.84 The number of
black pixels (representing aggregated nanoparticles) was enu-
merated by Image J software and expressed as a percentage of
the total number of pixels. This percentage corresponds to the
degree of aggregation visible by light microscopy. The method
was validated by preparing serial dilutions of an aggregated
nanoparticle and generating a standard curve of percentage
aggregation visible by microscopy vs. percentage aggregation
by serial dilution. See Supplementary Material (Appendix C)
for further details of the method.
2.4. Loading
2.4.1. SPDP Loading
The loading (i.e. the mean number of SPDP linker molecules
per nm2 surface area of GNP) was determined by a cleave-and-
analyze approach. First, a reducing agent (in this case excess
dithiothreitol or DTT) was used to cleave the pyridine-2-thione
moiety from each molecule of SPDP conjugated onto the surface
of the gold nanoparticle. The concentration of pyridine-2-thione
(assumed to be equivalent to that of SPDP) was then determined
by measuring its absorbance at 343 nm.85 Excess (non-conju-
gated) SPDP was removed by repeated centrifugation and
washing, prior to measurement. See Supplementary Material
(Appendix D) for further details of the method and calculations.
2.4.2. RNA Loading
The number of strands of RNA per nanoparticle, prior to
polyethyleneimine coating was determined using a detach-
and-analyze approach, prior to coating with polyethylene-
imine.15 Aliquots of the RNA-gold nanoparticle (1 mL each) were
incubated for 30 min at 30oC with either 0.05 M DTT solution in
PBS (pH 7.4, 0.01 % Tween-20™) or PBS (pH 7.4, 0.01 %
Tween-20™) alone without DTT (as a control). DTT is a reducing
agent that cleaves disulphide bonds thus releasing RNA from
the surface of the gold nanoparticle. Fluorescence signals from
RNA prior to release are quenched by the gold nanoparticle
surface plasmon resonance. A 200 µL aliquot was taken for
fluorescence measurement after incubation with DTT and PBS
control. The aliquot was centrifuged at 15 700 × g for 15 min at
4 °C to pellet the gold nanoparticles thus avoiding quenching
effects. Fluorescence of the supernatant was then measured
on a Glomax Multimode Detection System, using the Blue filter
(Excitation: 490 nm, Emission: 510–570 nm) (Promega Corpora-
tion Madison, Wisconsin, USA). The concentration of RNA was
calculated by plotting the difference in fluorescence (DTT
aliquot less control (PBS only) aliquot) on a standard curve of
fluorescently labelled RNA concentration vs. relative fluores-
cence units.86 See Supplementary Material (Appendix E) for
further details of the method and calculations.
2.5. Cell Uptake
Uptake of the nanoparticle by MT4 lymphocytes was assessed
by electron microscopy, fluorometry, flow cytometry, and fluo-
rescent and light microscopy.
2.5.1. Cells
MT4 lymphocytes (obtained from the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH from Dr Douglas
Richman) were grown at 37 °C in 5 % CO2 in RPMI 1640 medium
(GIBCO/Life Technologies, Grand Island, New York, USA)
containing sodium bicarbonate and L-glutamine, supplemented
with 10 % heat-inactivated fetal calf serum (Biochrom GmbH,
Berlin, Germany). Cells were split 1:10 every 3 days and regu-
larly monitored for viability and contamination. Cells were used
at the exponential phase of growth and with viability at least
95 %. The Countess™ Automated Cell Counter (Life Technol-
ogies, Grand Island, New York, USA) was used to determine cell
counts and viability.
2.5.2. Electron Microscopy
To study uptake of gold nanoparticles, 250 µL of the final
nanoparticle product was added to MT4 lymphocytes (5 mL at
3 × 105 cells mL–1 in a 25 cm2 cell culture flask) and incubated
overnight at 37 °C with 5 % CO2. The cell suspension was then
centrifuged for 5 min at 300 × g to form a pellet. The culture
medium was removed without disturbing the pellet and
replaced with excess 2.5 % glutaraldehyde. The mixture was
incubated at room temperature for 10 min, spun again and then
resuspended in fresh glutaraldehyde and incubated at 4 °C over-
night. The sample was then washed 3 times with phosphate
buffer and incubated for 1 h with 0.5 % osmium tetroxide. The
specimen was thereafter washed 3x with phosphate buffer,
dehydrated with increasing concentrations of acetone, infil-
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trated with epoxy resin, embedded in fresh resin and then poly-
merized in an oven for 8 h at 70 °C. Several sections were cut and
visualized on a JEOL 2100 High Resolution Transmission Elec-
tron Microscope.87
2.5.3. Flow Cytometry
MT4 lymphocytes (50 000 cells/well) were suspended in wells
of a microtitre plate with 200 µL complete RPMI. The cells were
then incubated overnight with 25 µL of untreated control
(RPMI only), RNA control (10 µM RNA only), uncoated
nanoparticle, without polyethyleneimine (3 nM), complete
nanoparticle (3 nM) and 10 % DMSO (dead cell control). The
cells were then harvested, washed twice by gentle centrifu-
gation, fixed with paraformaldehyde, resuspended in PBS and
stored at 4 °C until analysis by flow cytometry (within 24 h).
Uptake was determined on BD FACSCanto™ II (BD Biosciences
San Jose, CA, USA) instrument. Uptake of RNA was quantified
as the percentage of cells that were fluorescent.88
2.5.4. Fluorescent Microscopy
Cells were treated, harvested and washed as for flow
cytometry and then added to poly-L-lysine-coated microscope
slides. The slides were fixed with paraformaldehyde and then
viewed and photographed under a Nikon fluorescent micro-
scope (Nikon, Tokyo, Japan).89
2.5.5. Fluorometry
Flow cytometry and epifluorescent microscopy may fail to de-
tect uptake if the fluorescent signal per cell is below the limit of
detection for either technique. This may occur if only a small
number of gold nanoparticles are taken up per cell, for example,
or if there is quenching of the fluorescent signal of the
fluorescein-tagged intracellular RNA. In this case, the fluores-
cent signal may be amplified by examining the cumulative
uptake of a large number of cells (e.g. ³10 million cells). To
achieve this, 10 × 106 cells in a cell culture flask were exposed to
treatment and the cumulative fluorescent signal quantified by
pelleting and lysing the entire volume of cells post-incubation.
This method differentiates intracellular from extracellular RNA
by thoroughly washing the cells post-incubation (to remove
extracellular RNA, whether bound to nanoparticles or not).
Furthermore, the method differentiates ‘free’ RNA vs. RNA
bound to the surface of the gold nanoparticle, since the latter is
removed by centrifugation prior to measurement. The details of
the method are as follows:
MT4 lymphocytes were centrifuged at 200 × g and then
re-suspended in colourless RMPI with 10 % FCS at a concentra-
tion of 1 × 106 cells mL–1. The following nanoparticles and
controls were sonicated and added to flasks containing the MT4
lymphocytes in 10 mL RPMI/10 % FCS:
a. Buffer control: 200 µL PBS
b. Complete nanoparticle: 200 µL
GNP-PEG-SPDP-RNA-polyethyleneimine nanoparticle
(~3 nM)
c. Uncoated nanoparticle (without polyethyleneimine) 200 µL
AuNP-PEG-SPDP-RNA nanoparticle (~3 nM)
d. Free RNA: 200 µL RNA (~10 µM)
The RNA and nanoparticles were incubated with the cells for
varying periods (1, 6, 12 and 24 h). At the end of the incubation
period, the cells were washed 4 times (by centrifugation and
resuspension in PBS). An aliquot of the supernatant from the
final wash was stored for measurement of residual background
fluorescence. The cell pellets were frozen at –70 °C for at least
24 h. The cells were then thawed at room temperature and lysed
with CyQuant cell lysis buffer as per manufacturer’s instructions
(Invitrogen/Life Technologies, Grand Island, New York, USA).
The sample was centrifuged at 15 700 × g for 15 min at 4 °C to
pellet the gold nanoparticles which cause quenching of the
fluorescence signal. The fluorescence of the supernatant was
measured post-lysis. The background fluorescence was sub-
tracted from this value and the number of RNA strands released
per cell was quantified with the use of an RNA standard curve
(See Supplementary Material (Appendix E) for detailed calcula-
tions).
2.6. Cytotoxicity and Antiviral Activity
2.6.1. MTT Cytotoxicity (Methylthiazolyldiphenyl-tetrazolium
Bromide) Assay
The MTT assay was used to determine cytotoxicity (50 % inhib-
itory concentration, IC50), as previously described.
90 Briefly, 10 µL
of nanoparticle solution from each stage of synthesis was added
(in triplicate) to 90 µL complete media in wells of a microtitre
plate. The ‘outer’ wells of the plate were filled with PBS to avoid
‘edge’ effects. Serial 10-fold dilutions of the nanoparticles were
made. No treatment was added to the last column, which served
as the untreated control. Then 60 µL of MT4 lymphocytes (at 6 ×
105 cells mL–1) was added to each well. The plates were incubated
for 5 days at 37 °C in 5 % CO2 in a humidified incubator. At the
end of the incubation period, 15 µL of MTT salt (7.5 mg mL–1
dissolved in PBS by sonication) was added to each well using a
multichannel pipette. The plate was incubated for 1 h at 37 °C in
a CO2 incubator. Then 100 µL of media was removed without
disturbing the cells. The cells were lysed and the formazan
crystals solubilized with the addition 100 µL of acidified Tri-
ton™X-100 in isopropanol (50 mL isopropanol with 3 mL
Trito™n-X100 and 200 µL hydrochloric acid). The plates were
placed on a vibrating shaker for 10 min. Absorbance was read on
Glomax Absorbance Module (wavelength 540 and 690 nm). The
absorbance at 690 nm was subtracted from the absorbance at
540 nm and the results plotted on a graph. The IC50 was deter-
mined by linear extrapolation using the percentage cytotoxicity
at each concentration (% cytotoxicity at a given concentration =
absorbance at that concentration ¸ absorbance of untreated
cells × 100). Untreated cells (i.e. cells treated with PBS only)
were deemed to have 100 % viability. Growth medium without
phenol red was used in the assay to improve sensitivity of
absorbance readings.91
2.6.2. Antiviral Assay
Stock virus was prepared by harvesting supernatant of
HIV-infected MT4 lymphocytes at day 5 post-infection. The
virus was titrated by conventional TCID methods and stored at
–80 °C until use.90 The infectivity and cytopathic effect of the
virus used in the assay was confirmed by ensuring that the
viability of cells infected by HIV was at least 5-fold less than that
of mock-infected cells.90 All work involving HIV culture was
performed in the appropriate biosafety conditions.92–93
The antiviral assay to assess the cytoprotective (antiviral) effect
(50 % effective concentration, EC50) and selectivity index (SI) of
the nanoparticle was performed as previously described.90 The
final nanoparticle solution (10 µL) was added to 90 µL complete
media in 6 wells of a column of a microtitre plate. Serial 10-fold
dilutions were made. No treatment was added to the last
column, which served as the untreated control. Then 60 µL of
MT4 lymphocytes (at 6 × 105 cells mL–1) was added to all wells
(except outer wells, to avoid edge effects). To assess cytotoxicity,
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50 µL of RPMI was added to each well in the ‘upper’ half of the
plate (mock infection) while 50 µL of HIVIIIB at 300 Tissue Culture
Infective Dose (TCID)50 was added to the ‘lower’ half (HIV infec-
tion) to assess antiviral effect. The plates were incubated for 5
days at 37 °C in 5 % CO2 in a humidified incubator. At the end of
the incubation period, the MTT assay, as described above, was
performed to assess toxicity in mock (uninfected) cells and
cytoprotective effect in HIV-infected cells. The absorbance read-
ings were plotted on a graph and the IC50 and EC50 were deter-
mined by linear extrapolation.
The IC50 was determined as described above. The percentage
protection at each dilution was calculated as follows.90
Percentage protection at given concentration =
100 × (HT – HC)/Mc – HC)
where HT = average absorbance of treated, HIV infected cells at
that concentration, HC = average absorbance of untreated, HIV
infected cells, and Mc = average absorbance of untreated, mock
infected cells
The selectivity index = IC50/EC50
Untreated, uninfected cells and untreated, HIV-infected cells
were deemed to have 100 % and 0 % viability, respectively.90 AZT
(Azidothymidine) was used as a control (which required simul-
taneous preparation and incubation of a separate plate, using
the same reagents, cell preparation and virus stock).
3. Results and Discussion
3.1. Characterization
It was necessary to synthesize several batches of gold
nanoparticles for the experiments in this paper. The mean core
diameter of nanoparticles in all batches fell within the range
30–40 nm. Size, zeta potential and UV-vis absorption spectra
(absorbance and ëspr) of the nanoparticle at each stage of synthe-
sis are shown in Table 1 and Fig. 2. The average diameter in a
typical batch, as measured by electron microscopy was 30.08 nm
(range 19.07–47.44 nm, standard deviation 6.57 nm). Nano-
particles from a typical batch are shown in Fig. 3. Addition of the
cyclic peptide-SPDP conjugate to the gold nanoparticle solution
resulted in extensive, irreversible macroscopic aggregation,
precluding any further characterization, uptake or antiviral
studies.
There was significant aggregation of the polyethyleneimine-
coated nanoparticles when exposed to FBS (Figs. 4, 5 & 7). The
gold nanoparticles referred to in this experiment were studied in
its entirety, i.e. with PEG, SPDP, RNA and polyethyleneimine
coating, as described in the Synthesis section. Fig. 4 shows a dose
response effect between the degree of aggregation and the
percentage FBS in the medium. It is important to note that
aggregation occurred even at 10 % FBS (the typical concentra-
tion of serum used in cell culture media). Aggregation of
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Figure 2 UV-vis spectra of the gold nanoparticle construct at various stages of synthesis. The raw data were downloaded from the BioSpec Nano
instrument and plotted in Excel™. Absorbance values were normalized for differences in concentration by setting the absorbance at 450 nm to 1 for all
samples. (GNP = bare gold nanoparticle and PEG = PEGylated gold nanoparticle, i.e. gold nanoparticle conjugated to thiol-PEG-amine and SPDP =
SPDP linker conjugated to PEGylated gold nanoparticle and RNA = RNA conjugated to PEGylated gold nanoparticle via SPDP linker and PEI =
polyethyleneimine-coated nanoparticle following RNA conjugation
Table 1 Size, zetapotential and IC50 of gold nanoparticles.
Particle lmax Size by DLS Zeta potential IC50
/size /nm /mV /nM
Gold nanoparticle (GNP) 527 37 –21.4 0.56*
(39 nm)
GNP-PEG 530 76.6 +5.37 >1.72
GNP-PEG-SPDP 530 73.9 0.895 >0.40
GNP-PEG-SPDP-RNA 530 78.1 –7.6 >0.67
GNP-PEG-SPDP-RNA-polyethyleneimine 533 ** 13.5 >0.67 *
* Significant aggregation of the nanoparticle occurred in the cell culture medium.
** Measurement did not meet the quality criteria required for an acceptable determinaiton of size due to the polydispersity of the sample.
nanoparticles was visible by light microscopy within a few
minutes of exposure to cell culture medium and plateaued
within 24 h. Adjusting the pH of media to pH < 5 and pH >11
(by addition of 10 mM hydrochloric acid or sodium hydroxide,
respectively) reversed the aggregation, while Tween-20™
(0.01 %) did not. The presence of live cells did not have any effect
on aggregation.
3.2. Loading
An average PEGylated gold nanoparticle was decorated with
an average of 20350 SPDP linker molecules (or ~2.6 SPDP mole-
cules per nm2 nanoparticle surface area). This is in keeping with
published data on the density of PEG molecules per nm2
nanoparticle surface area of gold nanoparticle (even if one
assumes that SPDP binds to every available PEG on the surface
of the nanoparticle). Estimates of PEG loading vary from <1 to
~5 PEG per nm2 nanoparticle surface area, depending on the
molecular weight of the PEG, the shape and size of the
nanoparticle and measurement method.28 In particular, the
molecular weight (or length) of the PEG molecule drastically
influences grafting density, possible due to steric hindrance with
higher chain lengths,29 so that the density varies from 0.32
PEG nm–2 to 3.93 PEG nm–2 for PEG as the molecular weight of
the PEG decreases from 51400 to 2100 respectively. Therefore,
the loading of SPDP is in keeping with these data (taking into
account measurement errors and possibly a ratio other than 1:1
of SPDP conjugated to PEG).
On average, each nanoparticle contained ~1050 strands of
RNA (or 1 strand per ~4.8 nm2 of nanoparticle surface area),
prior to polyethyleneimine coating. Therefore, on average there
were 26 SPDP molecules per 10 nm2 nanoparticle surface area,
and only ~2 (i.e. 8 %) of these were conjugated to RNA (assum-
ing that RNA is conjugated to SPDP and not directly to the gold
nanoparticle surface). By comparison, Anderson’s group et al.15
found that there were 30–40 strands of RNA per 15 nm diameter
nanoparticle (or, by our calculations, approximately 1 strand of
RNA per 18–24 nm2 of nanoparticle surface area), suggesting
that the loading of RNA in their study was even less efficient.
However, any comparisons must take into account that the RNA
in Anderson’s study was double rather than single-stranded,
and that a different method of RNA quantification was used).
Increasing the concentration of RNA did not improve the load-
ing. Typically, <10 % of the RNA added to the reaction mixture
was conjugated to the gold nanoparticle and the rest remained
unbound and was detectable in the supernatant. Although Lee
et al. do not explicitly determine the proportion of RNA that
conjugates to the GNP,15 they provide sufficient data for the
calculation to be made. In their study, only 6 % of the RNA
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Figure 3 Electron micrograph of ~30 nm diameter polyethyleneimine-coated gold nanoparticles. The distribution of the diameter of the particles is
shown on the right.
Figure 4 Graph showing percentage aggregation (as determined by light microscopy and Image J software) at various concentrations of FBS. Data
presented as mean  ± 1 standard deviation of three independent experiments.
added to the reaction was conjugated to the surface of the GNP.
Therefore, the efficiency of RNA conjugation in our experiments
is in keeping with that of Lee et al.15 Further details may be found
in the section on RNA concentration in the Supplementary
Material (Appendix F).
3.3. Cell Uptake
Fluorometric measurements revealed that approximately 43
polyethyleneimine-coated nanoparticles were taken up per
cell (corresponding to ~45 000 strands of RNA) (Table 2). This
finding is consistent with electron microscopy enumeration of
uptake (~30 nanoparticles per cell, for example, in Fig. 7C). It is
difficult to compare these results to published data, for several
reasons. Firstly, there are relatively few studies that quantify the
number of gold nanoparticles taken up per cell.94 In most studies,
uptake is gauged by methods such as flow cytometry, fluores-
cent microscopy or functional effects, which do not explicitly
quantify the number of nanoparticles taken up per cell.
Secondly, the uptake of nanoparticles by cells is influenced by
various factors including nanoparticle concentration, clustering,
size, shape and surface functionalization/capping and cell type,
size95 and orientation,96 and experimental factors including
incubation period and temperature.67,94,97–98 In particular, uptake
appears to be significantly diminished in suspension cultures (as
in this paper) as opposed to adherent monolayers.99 Thirdly, the
method of enumeration may yield divergent results.96 It is there-
fore not surprising that estimates of nanoparticle uptake vary
widely, from as low as 45 nanoparticles (nanorods) per cell100
(comparable to the findings of this paper), to hundreds 101 or
thousands of nanoparticles per cell. 22,67,94,96,102
There was no significant uptake of free RNA and RNA bound
to nanoparticles not coated with polyethyleneimine (0 and <600
strands per cell, respectively). Uptake of RNA was below the
limit of detection by epifluorescent microscopy and flow
cytometry (Fig. 6). A series of experiments were undertaken to
improve uptake, without success. See Supplementary Material
(Appendix F) for further details of these experiments.
The preceding discussion is based on the assumption that the
RNA was efficiently and completely released from the nano-
particle surface. If this was not the case, then uptake may have
been underestimated by fluorescent methods (due to quenching
of the fluorescent signal by the gold nanoparticle). This may
explain, at least partly, the negative results on flow cytometry
and epifluorescent microscopy.
Light microscopy and electron microscopy showed significant
aggregation of the nanoparticles in the extracellular medium
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Figure 5 Black and white (8-bit) image of aggregated gold nanoparticles under light microscopy (A) and the transformed image used by ImageJ (B)
to estimate the 2-D surface area (16.43 %) of the aggregated nanoparticles (C).
Table 2 Fluorometric measurement of uptake of RNA and nanoparticles by MT4 lymphocytes.
Treatment Increase in RFU 1 post-lysis Estimated number of strands of Calculated number of
RNA taken up per cell nanoparticles taken up per cell 2
Buffer (negative control) 0 0 –
Free RNA 1 0 –
Uncoated nanoparticle (nanoparticle 5 <600 strands per cell 3 <1
without polyethyleneimine coating)
Complete nanoparticle (with 93 45 000 43
polyethyleneimine coating)
1 Relative fluorescence units (RFU).
2 Based on 1050 strands of RNA per nanoparticle and assuming 100 % detachment of RNA from the surface of all nanoparticles.
3 Limit of detection = 600 strands per cell (corresponding to RFU = 5.3).
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Figure 6 Epifluorescent microscopy (left) and flow cytometry results (right) showing untreated MT4 lymphocytes (A) and lymphocytes treated with
polyethyleneimine-coated gold nanoparticles containing fluorescently tagged RNA (B). The nuclei of cells stained with DAPI are clearly visible on
epifluorescent microscopy (blue). Visualization using the fluorescein filter showed no obvious uptake of the polyethyleneimine-coated gold
nanoparticle. The corresponding flow cytometry results show no difference between the untreated control (A) and cells treated with the
polyethyleneimine-coated gold nanoparticles (B) (3.8 vs. 3.5 %). By comparison, in an experiment with FITC labelled gold nanoparticles (C), there is
obvious uptake (indicated by green fluorescence) and the corresponding flow cytometry results indicate that 96.6 % of treated cells had positive
fluorescence (shown in blue, in this case). (See Acknowledgements section.)
Figure 7 Electron micrograph of gold nanoparticles show extensive extracellular aggregation (A and B), while only occasional nanoparticles are
found within a vesicle in the cytoplasm (C). The aggregates are visible on light microscopy as well (D).
(Fig. 7). Another study using polyethyleneimine-coated gold
nanoparticles for gene delivery has documented similar aggre-
gation issues, which the authors attributed to the lyophilization
and reconstitution process used in the preparation of the
nanoparticle.103 This is not a consideration since lyophilization
was not used in our study. Another study attributed the aggre-
gation to polyethyleneimine reaching its saturation point in the
reaction mixture, and suggested optimization of the loading
density of the polyethyleneimine on the gold nanoparticle
surface (determined to be 1000 molecules of polyethyleneimine
per gold nanoparticle in their system).104 This limit was not
exceeded in our study. Extracellular aggregation of the nano-
particle may have contributed significantly to the seemingly
poor uptake by lymphocytes.
3.4. Cytotoxicity and Antiviral Activity
The nanoparticles did not display significant toxicity (Table 1)
or antiviral activity (Fig. 8) which was expected, given the poor
uptake.
4. Conclusion
In this paper, a multifunctional nanoparticle, designed to facili-
tate transfection of a single-stranded RNA into MT4 lympho-
cytes, was synthesized and characterized. The loading of the
RNA per nanoparticle (1 strand per ~4.8 nm2 of nanoparticle
surface area) exceeded that of Lee et al.15 (1 strand per ~18 nm2
and note: the RNA used in their study was double-stranded).
The multifunctional nanoparticle successfully transfected MT4
lymphocytes, although at low efficiency. Measurement of fluo-
rescence after lysis of treated cells showed uptake of ~45 000
strands of RNA (or 43 nanoparticles) per cell. This degree of
uptake was below the limit of detection by flow cytometry and
epifluorescent microscopy and was probably insufficient to
exert a significant cytotoxic or antiviral effect. However, other
reasons, such as quenching of fluorescent signal and lack of
potency of RNA construct, may also explain the negative uptake
and antiviral effect, respectively.
The limited uptake and antiviral effect was probably due to
significant aggregation of the polyethyleneimine-coated nano-
particles in the cell culture medium. Similar aggregation issues
with polyethyleneimine-coated nanoparticles have been
encountered in previous studies.42,103 It has been shown that
aggregation has an effect on uptake, and that such effects are
dependent not only on the size of the aggregates, but also on
cell type.105 Furthermore, aggregation may be associated with
leeching of the polyethelenimine from the surface of nano-
particles, with subsequent loss of its protective effect and thus
degradation of RNA by nucleases (although we did not confirm
this experimentally). In our study, aggregation was quantified
by photographic software and showed a dose response effect to
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Figure 8 Graphical representation of results of the antiviral MTT assay. (A) Results for the polyethyleneimine-coated nanoparticle, which show no
activity or cytotoxicity at the concentrations tested. The AZT control (B) has potent antiviral activity (EC50 = 0.05 µM) and is toxic only at high concen-
trations (IC50 = 100.7 µM), with selectivity index (IC50/EC50) = 2014.
increasing concentration of FBS, which suggests that the aggre-
gation is induced by serum factors, most likely proteins. Attach-
ment of the cyclic peptide ligand to the surface of the poly-
ethyleneimine-coated gold nanoparticle exacerbated the aggre-
gation.
It must be noted that we did not study whether particles were
taken up singly, in clusters or as aggregates, nor did we study
their fate upon entry into the intracellular environment (particu-
larly with regard to whether aggregation increased or decreased
over time, and how quickly, if at all, they exited the cell). Further-
more, we did not study the effect of aggregation on the release of
RNA from the surface of the nanoparticle. If RNA release was
hampered due to aggregation, this may have had led to quench-
ing of fluorescent signals and subsequent underestimation of
uptake. These are aspects for further study, probably by the use
of ex vivo, real-time imaging techniques.106
The conjugation of RNA to the gold nanoparticle surface via
the SPDP linker molecule was relatively inefficient (peaking at 1
strand per 4.8 nm2 of nanoparticle surface area). This means that
the RNA was conjugated to only ~8 % of SPDP binding sites
available on the surface of the gold nanoparticle. Over 90 % of
the RNA fails to conjugate and remains in the supernatant
post-reaction. Another group using a similar strategy to link
RNA onto gold nanoparticles revealed a similar low efficiency
(by our calculation, only 6 % of available SPDP binding sites
were conjugated to RNA). Increasing the input concentration of
RNA did not lead to an increase in RNA loading per
nanoparticle. This is a major limitation compared to transfection
using dendrimers for example, where effectively all the RNA is
complexed into the dendriplex.31
Furthermore, the inefficient binding of RNA to the surface of
the gold nanoparticle may be a mechanistic factor that contrib-
utes to the aggregation of the nanoparticle. The low density of
RNA (as evident by relatively high zeta potential values) implies
that the surface of the gold nanoparticle may not have sufficient
negative charge to retain the positively charged polyethylene-
imine upon its surface (which may have led to partial leaching of
the polyethyleneimine and aggregation – see Fig. S3 in Supple-
mentary Material). The negative charge of gold nanoparticles at
the RNA conjugation stage (prior to polyethyleneimine coating)
in our experiments did not exceed ~8 mV. By comparison,
the zeta potential achieved in a layer-by-layer (non-covalent)
approach by Elbakry et al. was at least double this value (–20 to
–40 mV).42 However, other factors, such as the size of the gold
nanoparticle (either as single entities or clusters) and the length
of polyethyleneimine are likely to play a role since the wrapping
process is governed by the length of the polymer relative to
surface curvature of the nanoparticle.42
The reasons for the low conjugation of RNA to the linker
molecule may include steric hindrance or charge repulsion,
which prevent high-density packing of covalently bound RNA
molecules. By contrast, a layer-by-layer approach facilitates
higher density RNA packing due to the presence of the posi-
tively charged polyethyleneimine in the underlying layer
(which may counteract charge repulsion). Furthermore, the
density and orientation of RNA packing in a layer-by-layer
approach are not limited by the availability of linker molecules
for covalent bond formation. Possibly, for these reasons, there
were 780 siRNA strands per 15 nm nanoparticle (i.e. ~1.1 RNA
per nm2) in Elbakry’s layer-by-layer approach, which is more
than 5-fold greater loading than achieved by the approach in our
paper.
Although the construct described in this paper had limited
uptake and antiviral effect, details provided in terms of synthesis
and characterization of the nanoparticle and quantification of
aggregation may be useful for the assessments of nanoparticles
with similar issues. Further studies are required to understand
the factors that may explain and improve the loading of RNA
onto the surface of gold nanoparticles using the approach
adopted in this paper. In addition, it will be of interest to study
whether aggregation may be prevented by increasing the load-
ing of the RNA, or alternatively replicating this study with other
cationic polymers (including low molecular weight and linear
polyethyleneimine). Finally, it is not known whether this
phenomenon is unique to single-stranded RNA and studies
with double-stranded RNA and DNA may yield more favour-
able results.
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Appendix A: Confirming PEGylationby Gel Electrophoresis and Colloidal Stability Test 
PEGylation of the multifunctional nanoparticle is essential to ensure its stability in physiological 
solutions.1  Successful PEGylation was conveniently determined by the Colloidal Stability Test, in which 
the colour of a solution of bare (non-PEGylated) gold nanoparticles rapidly changes from wine red/pink 
to purple in the presence of high salt concentrations (indicating the formation of aggregates). PEGylated 
nanoparticles are stable in solutions containing high concentration of salts, and do not undergo any visible 
colour change (Figure S1). 
 
 
Figure S1: Colloidal Stability Test: A 1 ml solution of bare gold nanoparticles (GNP), rapidly changes to 
a purple colour upon the addition of 100 µL 10x PBS (GNP + 10x PBS), while PEGylated gold 
nanoparticles (GNP-PEG) do not (GNP-PEG + 10x PBS). 
 
Successful PEGylation may also be confirmed visually on gel electrophoresis since bare citrate capped 
gold nanoparticles are negatively charged2 while PEGylated gold nanoparticles are neutral (Figure S2). A 
2 % agarose gel was prepared with TBE (Tris/Borate/EDTA) buffer (pH = 8.3). A 10 µL aliquot of 
nanoparticle solution was mixed with an equal volume of 40% w/v sucrose and then loaded into the well 
of the agarose gel. The gel was run for 40 minutes at 120 V. A sufficiently high concentration of gold 
nanoparticle solution was used to permit visualisation and photography of the “bands” on the gel. 
 
Gel electrophoresis was also performed to confirm conjugation of RNA to gold nanoparticles i.e. to show 
that the fluorescent bands (RNA) co-localised with visible gold nanoparticle bands. However, 
fluorescence was not observed, probably due to the low number of RNA molecules per gold nanoparticle 







Figure S2: Gel electrophoresis of gold nanoparticles showing migration of negatively charged bare gold 
nanoparticles towards the positive pole. PEGylated gold nanoparticles (left lane) and PEGylated gold 


























Appendix B: Peptide Synthesis3 
Design of the Peptide Ligand: Targeting CD4 Cells 
A synthetic peptide, that specifically binds the CD4 receptor, was attached to the gold nanoparticle to 
potentially enhance receptor-mediated endocytosis and uptake of the nanoparticle by CD4+ MT4 
lymphocytes. The design of the peptide was based on systematic exploration of the variable domains of 
an anti-CD4 mAb by the “Spot” method.4-8 This peptide has been shown to cause dose dependent 
inhibition of IL2 secretion by CD4+ cells, inhibition of HIV-1 promoter activation, specific, dose-
dependent binding to soluble CD4 in an ELISA assay and dose-dependent inhibition of binding to soluble 
CD4 by anti-CD4 mAb in an ELISA inhibition assay.5 An AAC “tail” links the peptide to the 
polyethyleneimine via an SPDP linker molecule. The peptide was synthesized by routine FMoc Solid 
Phase Synthesis3, 9-12 on a CEM microwave peptide synthesizer13-14 and cyclised by on-resin iodine-
oxidation of cysteine residues close to the N and C termini of the peptide.7, 15 
 
Reagents 
9-fluorenylmethoxycarbonyl (FMoc) protected amino acids and coupling reagents were purchased from 
GLS Biochem Systems. Solvents were purchased from Sigma-Aldrich. 
 
Peptide Sequence 
The sequence of the peptide is as follows:KC*LTTFGVHWVRQSC*KAAC#. The peptide consists of 
10 (~53%) hydrophobic, 4 (~21%) polar, 4 positively charged and 0 negatively charged amino 
acids.16The “inner” cysteines that are involved in the cyclization reaction,  are shown as C*, and the  “tail” 
cysteine that links to the gold nanoparticle surface is shown as C#. 
 
Solid PhasePeptide synthesis 
FMoc Solid Phase Peptide synthesis was carried out in a C to N direction on a CEM microwave peptide 
synthesizer at a 0.1 mmol scale. Rink amide resin was used as the solid support     system.13-
14Deprotection was achieved by 20%  
piperidine/DMF(dimethylformamide)(v/v)13, 17 and coupling by 1:1:1 amino acid/HBTU(N-[1H-
benzotriazol-1-yl)(dimethylamino)methylene]-N-methyl-methanaminium hexafluorophosphate N-oxide)/ 
DIPEA (N,N-diisopropyl ethylamine) in DMF.13Table S1 provides the details of side chain 
protection/deprotection strategy, while Table S2 lists the microwave synthesis conditions. DMF washes 







Table S1: Side Chain Protection/Deprotection3, 11 
# 
(L-R) 
Amino Acid Letter 
(label) 
Symbol Protection Deprotection 
1 Lysine K Lys Mtt 95%TFA 
2 Cysteine C* Cys Mmt 1% TFA 
3 Leucine L leu NONE NONE 
4 Threonine T Thr tBu 95%TFA 
5 Threonine T Thr tBu 95%TFA 
6 Phenylalanine F Phe NONE NONE 
7 Glycine G Gly NONE NONE 
8 Valine V Val NONE NONE 
9 Histidine H His Trt 95%TFA 
10 Tryptophan W Trp Boc 95%TFA 
11 Valine V Val NONE NONE 
12 Arginine R Arg Pbf 95% TFA 
13 Glutamine Q Gln Trt 95% TFA 
14 Serine S Ser tBu 95%TFA 
15 Cysteine C* Cys Mmt 1% TFA 
16 Lysine K Lys Boc 95%TFA 
17 Alanine A Ala NONE NONE 
18 Alanine A Ala NONE NONE 
19 Cysteine C# Cys Trt 95% TFA 
Boc tert-butoxycarbonyl, Mmt 4-methoxytrityl, Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, 
Pmc 2,2,5,7,8-pentamethylchroman-6-sulfonyl, tBu tert-butyl, TFA trifluoroacetic acid, Trt 












Table S2: Microwave Conditions for Coupling/Deprotection13-14 
 Power (Watts) Temperature (°C) Time (s) 
Single Coupling (all 
amino acids except 
arginine) 








De-protection 40 73 180
Total Run Time  26 hours 
 
 
On Resin Cyclization15, 18-19 
To avoid side-reactions, cyclization was performed on resin with the N-terminal amino acid still protected 
with the FMoc group. A disulphide bond was formed between two the cysteine residues (C*) at positions 
2 and 15, by iodine-oxidation. The details of the procedure are as follows: 
1. The resin was swelled with DMF (3x). 
2. Mmt was cleaved from the “inner” cysteines using 1% TFA. 
3. The peptide was oxidized with I2 (10 eq) in DMF for 1.5 hours, with gentle stirring at room 
temperature. 
4. The resin was washed thoroughly with DCM (dichloromethane) (5x), CCl4 (5x) and DMF (10x) 
to remove iodine. 
5. Peptides were cleaved from the resin and the remaining side chain protecting groups removed 
with 1% TIS(tri-isopropylsilane) + 1% thioanisole + 1% 1,2 ethanedithiol +  95% TFA in DCM 
for 2 hours.13 
 
The peptides were purified on a Younglin ACME 9000 instrument using an ACE C-18 reverse phase 
semi-preparative High Performance Liquid Chromatography (HPLC) column and mass spectra were 
obtained on a Bruker ESI-QTOF mass spectrometer and Shimadzu Prominence LC-MS System. The 







SPDP is an amine-sulfhydryl crosslinking molecule that has an amine reactive portion (N-
hydroxysuccinimide (NHS) ester) and a sulfhydryl-reactive portion (2-pyridyldithio group) 
The 2-pyridyldithio group reacts optimally with sulfhydryl- containing molecules, such as cysteine, 
between pH 7 and 8. The cysteine at the end of the “AAC” tail of the cyclic peptide was conjugated to 
SPDP as follows: 
 
25µL of 20mM SPDP solution was added to 2 mg cyclic peptide dissolved in 1 mL of PBS. The mixture 
was incubated for 30 minutes at room temperature. Excess SPDP was then removed by Sephadex G-25 
PD-10 desalting column (GE Healthcare Life Sciences, Pittsburgh, Pennsylvania, USA). Then the 
solution was added to 1 mL polyethyleneimine coated gold nanoparticle and incubated overnight to allow 
conjugation of the peptide-SPDP with the amine side chains of polyethyleneimine via the NHS ester of 
























Appendix C: Aggregation and its quantification by Light Microscopy and Photographic Software 
Nanoparticle aggregation is often overlooked or understated; however, the complexity of the mechanisms 
and factors involved, and the importance of the phenomenon, are now being recognised.1  In this study, it 
is postulated that aggregation occurs whenseveral nanoparticles are attracted to the same 
polyethyleneimine molecule.20  The proposed mechanism is shown in Figure S3. 
 
Aggregation may be detected by colour change, spectrophotometry, dynamic light scattering, nanoparticle 
tracking analysis21 and microscopy (electron or light). In this study, light microscopy was found to be a 
convenient method to quantify aggregation since it is quick, inexpensive, can be performed in situ 
(without requiring transfer of the sample to a cuvette), does not destroy or disturb the sample (so that 
incubation can be continued and the measurement repeated at varying points of time).It requires a small 
sample volume and has no limit in terms of size and shape of the particles. Moreover, it is unlikely that 
particles larger than 1 micron will be internalised, and 1 micron is incidentally the approximate maximum 
resolution of a light microscope (at 100x magnification). Additionally, it is the total number of 
nanoparticles contained within the sum of all aggregates that is of concern (since these may no longer be 
taken up), rather than the number of aggregates, (a large number of small aggregates may contain the 
same number of nanoparticles as a small number of large aggregates). The number of nanoparticles 
contained within an aggregate is directly proportional to its total volume. Furthermore, if the assumption 
is made that aggregates are formed and orientated randomly in three dimensional space, then the surface 
area is directly proportional to the volume of the aggregate and hence to the total the number of 
nanoparticles contained within it. Therefore, a two dimensional photograph of aggregates under light 
microscopy will be a good approximation of the total number of aggregated gold nanoparticles. 
 
It must be noted that the assumption that number of particles within an aggregate is linearly proportional 
to its size (and mass) cannot be taken for granted, and is certainly not true if aggregates are formed as 
self-similar (mass-fractal) structures, in which case power-law (rather than linear) relationships are 
characteristic.1  Nevertheless, in the absence of certainty about the exact mechanism of aggregation (and 
the effect of “external forces”), such assumptions can only be tested by quantification within a defined 
experimental setup. Findings may certainly not be extrapolated to experimental setups where the 
































Figure S3:Aggregation occurs when several nanoparticles are attracted to the same polyethyleneimine 
molecule.20, 22-25A. Non-aggregated gold nanoparticles coated with polyethyleneimine. Exposure to serum 
proteins is hypothesised to result in leeching of polyethyleneimine from the surface of nanoparticles (B, 
C). This results in the disorderly and random association of several (>1) nanoparticles with the same 
molecule of polyethyleneimine, resulting in the formation of aggregates (D, E). The polyethyleneimine 
used in this paper is branched but is shown here as a linear molecule for simplicity. The aggregates 
shown here (D and E) consists of 2 nanoparticles (a doublet); the number of nanoparticles contained in 
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Quantification of aggregation by light microscopy was performed as follows 
1. Aliquots of the nanoparticle solutions weredispensed in triplicate into the well of a clear flat-
bottomed microtiter plate. 
2. The wells were then viewed under a Leica DMIL light microscope (Leica, Wetzlar, Germany) at 
200x magnification. 
3. Light intensity and course focus were fixed during observation to avoid well to well variation in 
viewing conditions. 
4. Representative images were captured on a Zeiss Axiocam 105 camera (Carl Zeiss, Oberkochen, 
Germany). 
5. The images were imported into Image J software in an 8-bit grayscale format. 
6. The black:white threshold was adjusted by the maximum entropy method.26The choice of 
threshold adjustment method was made empirically. The method that most accurately represented 
the percentage of black pixels that corresponded to visual approximation was chosen. The 
important point is that data using different methods cannot be compared. Therefore, the method, 
once chosen, was used for all experiments in which data was compared. 
7. The number of black pixels (representing aggregated nanoparticles) was enumerated by Image J 
software and expressed as a percentage of the total number of pixels. 
8. In order to generate a standard curve, serial, 2-fold dilutions of a highly aggregated gold 
nanoparticle solution were made with PBS, in the wells of a clear, flat bottom microtiter plate. 
The solution was thoroughly mixed at each step to ensure that aggregated nanoparticles were 
likewise diluted. Dilutions were prepared in triplicate. Photographs were taken of each dilution 
and the percentage black pixels was determined as described above (steps 1-7).   The percentage 
black pixels was plotted against serial dilutions of the aggregated gold nanoparticle (log 
transformed to base 2) (Figure S4). The method showed excellent correlation (r = 0.99) between 
percentage black pixels vs. actual aggregation of serially diluted aliquots in the range of 0.3 to 50 







Figure S4:Graph showing linear relationship between serially diluted aggregated gold nanoparticles and 
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Figure S5:Representative images of serially diluted aggregated nanoparticles under 200x magnification, 
the corresponding 8-bit grayscale images with the black-white threshold adjusted by the maximum 





Appendix D: SPDP Loading 
The loading (SPDP linker molecules per nanoparticle) was determined by measuring the concentration of 
pyridine-2-thione which is released from the surface of the gold nanoparticle when exposed to the 
reducing agent dithiothreitol (DTT). 
The assay is performed as follows: 
1. SPDP was conjugated to the PEGylated nanoparticle as described in the synthesis section. For the 
purposes of this experiment, the volume of SPDP and PEGylated gold nanoparticle used in the 
reaction was increased (without altering the concentration of the reactants) so that a “measurable” 
concentration of pyridine-2-thione would be released at the end of the assay. A “measurable” 
concentration of pyridine-2-thione was defined by an absorbance reading at least 3 standard 
deviations greater than the “Blank”. In a typical experiment, 20 mL of reaction product (i.e. a 
mixture of 10 mL SPDP + 10 mL GNP-PEG), re-suspended after final centrifugation to a volume 
of 1mL, was sufficient. It is important that the volume of the reaction mixtures be adjusted, rather 
than the concentration of SPDP. SPDP is poorly soluble in water; increasing the concentration 
excessively results in precipitation and spurious results. 
2. At the end of the reaction described in step one, the solution was repeatedly washed by 
centrifugation and resuspension in PBS-Tween-20™ (0.01%) to remove excess SPDP. A 500 µL 
aliquot of the supernatant after the last spin was tested for the presence of SPDP using the 
pyridine-2-thione assay (as described in the steps below). An absorbance value of < 0.01 (or a 
reading within 1 standard deviation of the “Blank”) was regarded as suitable. Typically, 4 washes 
were required for adequate removal of excess SPDP. 
3. After the last wash, the gold nanoparticle solution (GNP-PEG-SPDP) was re-suspended in 1 mL 
PBS/Tween, vortexed thoroughly, and then divided into 2 x 500 µL aliquots. 
4. 1 aliquot of the gold nanoparticle solution was mixed with 5 µL PBS (labelled GNP-PBS); the 
other aliquot of the gold nanoparticle solution (labelled GNP-DTT) was mixed with 5 µL DTT 
(15 mg/mL). 
5. The mixed solutions were incubated at room temperature for 15 minutes. 
6. After exactly 15 minutes, the aliquots were centrifuged until the supernatant was clear and the 
gold nanoparticle formed a distinct pellet. 









8. The difference in absorbance was calculated as follows: 
Difference in absorbance = GNP-DTT – (GNP-PBS) 
Where GNP-DTT = mean absorbance of supernatant of GNP solution treated with DTT 
GNP-PBS = mean absorbance of supernatant of GNP solution treated with PBS 
PBS-TWEEN was read as “Blank”. 
9. The molar concentration of the SPDP was then calculated as follows: 
Molar concentration (in mM) = difference in absorbance ÷ (8.08 mM-1cm-1 x path-length in cm), 
where 8.08 x 10-3M-1cm-1 is the“extinction coefficient” or molar absorptivity for pyridine-2-
thione at 343 nmand the path-length, when using the BioSpec Nano in the 0.7 mm mode. 
 
In a typical experiment, the molar concentration of pyridine-2-thione in the final 1 mL aliquot was found 
to be 407 µM or 407 000 nM (based on mean absorbance difference of 0.23 units). The concentration of 
gold nanoparticle in the same aliquot was 20nM (as determined by absorbance measurements).27  
Therefore, each nanoparticle was decorated with an average of (407 000 ÷ 20 =) 20350 SPDP linker 






















Appendix E: Details of the Method to Determine RNA Concentration to Calculate Loading and Uptake 
It was necessary to measure the concentration of RNA to allow for the determination of RNA loading per 
nanoparticle and to assess cellular uptake (as an alternative to flow cytometry and epifluorescent 
microscopy). The RNA was synthesised with a fluorescein tag at the 3’ end, which allows for 
quantification by generation of a standard curve of fluorescence. This was measured as relative 
fluorescence units (RFU vs. RNA concentration and determined by absorbance and serial dilutions; a 
representative graph is presented in Figure S6. Fluorescence is significantly more sensitive than 
absorbance for RNA quantification. The approximate lower limit for absorbance-based quantification 
using the Biospec Nano is given as 15 ng/µL of ds DNA based on the 0.7 mm path length method. This 
equates to a limit of quantification of RNA used in this experiment to approximately 2.8 µM.  By 
contrast, measurement by fluorescence (using the method described in this section) is at least 1000x more 
sensitive which allows quantification in the nanomolar range (from as low as 1 nM). 
 
The concentration of the stock RNA (which was synthesised in the micromolar scale) was determined by 
UV spectroscopy on the BioSpec Nano. An adjustment was made for the absorbance of fluorescein using 
the on-board software. The ratio of absorbance at 260nm to absorbance at 280nm allows for the 
determination of the concentration of RNA using the Beer-Lambert Law.28The concentration of a typical 
aliquot of RNA using this method was determined to be 888 ng/µL. The molecular weight of the RNA = 
5315g/mol or 5315ng/nmol. Therefore, the concentration of the RNA = 888/5315 nmol/µL = 167µmol/L 
= 167µM.  
 
The concentration was adjusted to 10µM by addition of RNAse free deionised water. Eight serial 10 fold 
dilutions were made, in triplicate, in a black microtiter plate and the fluorescence read in the Glomax 
Multimode Detection System using the Blue filter (Excitation 490nm/Emission 510-570nm). The 
readings were log transformed (base 10) and plotted in Excel™ and the RNA concentration then 
determined by linear extrapolation on the logarithmic scale. 
 
For determination of RNA loading, the concentration of released RNA was determined (e.g. 1200nM) and 
divided by the concentration of gold nanoparticle (e.g. 1.14 nM) to yield the number of strands of RNA 
per gold nanoparticle (e.g. 1053). 
 
To determine uptake, the concentration of RNA was similarly determined in the supernatant following 





number of nanomoles of RNA per million cells (e.g. 7.5 x 10-5 nmoles per million cells) which 
corresponds to 45 000 strands of RNA per cell. 
 
The limit of detection of RNA uptake per cell was calculated based on the lower limit of detection of 
RNA of 1nM, corresponding to a Relative Fluorescence Units (RFU) = 5.3. Moreover, RFU values <7 
(i.e. falling within 2 standard deviations away from the mean) are likely due to instrument “noise” rather 
than biological factors. Therefore, only readings > 7 RFU above the mean were regarded as significant. 







Figure S6:Graph showing log-linear relationship between RNA concentration (in pM) and relative 
fluorescence units (dimensionless) over a wide range (from about 1 nM to 10 µM). Fluorescence readings 
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Appendix F: Optimisation 
A series of experiments were carried out, in which the synthesis procedure and uptake conditions were 
varied, in an attempt to improve aggregation and uptake.  
 
Size of GNP 
In a previous study to determine the effect of nanoparticle size on uptake into Hela cells, nanoparticles 
with diameter 30–50 nm were taken up more readily than smaller or larger particles.29 Therefore, the 
assumption was made that the nanoparticles used in this paper (30-40nm) would achieve similar results. 
Nevertheless, the synthesis procedure (as described in the Synthesissection) was repeated with 
nanoparticles of diameter 15nm, without significant improvement in aggregation and uptake. 
Nanoparticles of size 15nm were synthesised using the same method as described for 30-40 mm gold 
nanoparticles, except that the amount of sodium citrate was doubled.30 The concentration of reagents for 
each of the subsequent steps was adjusted to take into account the surface area of 15nm particles. 
 
RNA concentration 
It is important to optimise the conjugation of the RNA to the gold nanoparticle, since synthetic RNA is 
expensive and produced in small quantities (usually in the nanomolar or micromolar scale). The 
proportion of RNA that binds to the surface of the nanoparticle (as opposed to the RNA that fails to bind) 
was determined by measuring the concentration of the RNA in the supernatant pre and post reaction. 
 
In a typical reaction, only ~1.2 µM of 15 µM (i.e. 8%) of RNA added per reaction, conjugated to the gold 
nanoparticle. The rest (92%) of the RNA remains in the supernatant. This was confirmed by measuring 
the concentration of the RNA in the supernatant, both by fluorescence and absorbance. Lee et al. do not 
explicitly determine the proportion of RNA that conjugates to the GNP.31  However, they provide 
sufficient data for the calculation to be made. Based on reaction of 15 µM RNA and 30 nM GNP in 400 
µL buffer and resulting ~30 strands of RNA per particle, the proportion of RNA conjugated to the surface 
of the GNP was calculated to be 6%. Therefore, the efficiency of RNA conjugation in our experiments is 
in keeping with that of Lee et al.31  Increasing the concentration of RNA did not improve the loading. 
 
Polyethyleneimine concentration 
The concentration of polyethyleneimine optimised for coating in a previous study was 1 mg 





polyethyleneimine since a positively charged nanoparticle was required to facilitate cellular uptake. The 
zeta potential of the nanoparticle was only +13.5 mV, even when synthesised with polyethyleneimine at 1 
mg/mL (compared to a zeta potential of ~+60 mV achieved by a layer-by-layer approach.23  Increasing 
the concentration of polyethyleneimine (up to 10 mg/mL) resulted in an increase in zeta potential (~23.6 
mV). However, the aggregation of the nanoparticleswas exacerbated and there was no improvement in the 
uptake (as determined by flow cytometry). Therefore, the optimal concentration of 1 mg/mL, as described 
by Elbakry et al.23 was used in subsequent experiments. 
 
Treatment Conditions 
Uptake was optimal with treatment duration of 24 hours (compared to 1, 2 hours and 4 hours). The use of 
serum-free OptiMEM™ media did not improve uptake (as determined by epifluorescent microscopy). 
The experiments were repeated with an adherent cell line (a human cervical epithelial carcinoma cell line 
(Hela), obtainedthrough the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HeLa 
CD4(HT4-6C) from Dr Bruce Chesebro).32-33  However, the nanoparticle was not taken up by this cell 



























1. Moore, T. L.; Rodriguez-Lorenzo, L.; Hirsch, V.; Balog, S.; Urban, D.; Jud, C.; Rothen-
Rutishauser, B.; Lattuada, M.; Petri-Fink, A., Nanoparticle colloidal stability in cell culture media 
and impact on cellular interactions. Chemical Society reviews 2015,44 (17), 6287-305. 
2. Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; Mirkin, C. A., Gold 
nanoparticles for biology and medicine. Angew Chem Int Ed Engl 2010,49 (19), 3280-94. 
3. Sewald, N.; Jakubke, H.-D., Peptide Synthesis. Wiley-VCH Verlag GmbH & Co. KGaA: 2009; p 
175-315. 
4. Monnet, C.; Laune, D.; Laroche-Traineau, J.; Biard-Piechaczyk, M.; Briant, L.; Bes, C.; 
Pugniere, M.; Mani, J. C.; Pau, B.; Cerutti, M.; Devauchelle, G.; Devaux, C.; Granier, C.; 
Chardes, T., Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal 
antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J Biol Chem 
1999,274 (6), 3789-96. 
5. Bes, C.; Briant-Longuet, L.; Cerruti, M.; De Berardinis, P.; Devauchelle, G.; Devaux, C.; Granier, 
C.; Chardes, T., Efficient CD4 binding and immunosuppressive properties of the 13B8.2 
monoclonal antibody are displayed by its CDR-H1-derived peptide CB1. FEBS Lett 2001,508 (1), 
67-74. 
6. Bes, C.; Briant-Longuet, L.; Cerutti, M.; Heitz, F.; Troadec, S.; Pugniere, M.; Roquet, F.; Molina, 
F.; Casset, F.; Bresson, D.; Peraldi-Roux, S.; Devauchelle, G.; Devaux, C.; Granier, C.; Chardes, 
T., Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide 
synthesis and site-directed mutagenesis. J Biol Chem 2003,278 (16), 14265-73. 
7. Albericio, F., Developments in peptide and amide synthesis. Curr Opin Chem Biol 2004,8 (3), 
211-21. 
8. Boschek, C. B.; Apiyo, D. O.; Soares, T. A.; Engelmann, H. E.; Pefaur, N. B.; Straatsma, T. P.; 
Baird, C. L., Engineering an ultra-stable affinity reagent based on Top7. Protein Eng Des Sel 
2009,22 (5), 325-32. 
9. Wellings, D. A.; Atherton, E., Standard Fmoc protocols. Methods Enzymol 1997,289, 44-67. 
10. Fields, G., Solid-phase peptide synthesis. Molecular Biomethods Handbook 1998, 527-545. 
11. Amblard, M.; Fehrentz, J. A.; Martinez, J.; Subra, G., Methods and Protocols of modern solid 
phase peptide synthesis. Mol Biotechnol 2006,33 (3), 239-254. 
12. Rapley, R.; Walker, J. M., Molecular Biomethods Handbook. 2nd ed.; Humana Press: Totowa, 
NJ, 2008; p xx, 1124 p. 
13. Muthusamy, K.; Albericio, F.; Arvidsson, P. I.; Govender, P.; Kruger, H. G.; Maguire, G. E.; 
Govender, T., Microwave assisted SPPS of amylin and its toxicity of the pure product to RIN-5F 
cells. Biopolymers 2010,94 (3), 323-30. 
14. Pietersen, L. K.; Govender, P.; Kruger, H. G.; Maguire, G. E. M.; Wesley-Smith, J.; Govender, 
T., Peptide Functionalised Gold Nanoparticles: Effect of Loading on Aggregation and 
Proteolysis. International Journal of Peptide Research and Therapeutics 2010,16 (4), 291-295. 
15. Galanis, A. S.; Albericio, F.; Grotli, M., Enhanced microwave-assisted method for on-bead 
disulfide bond formation: synthesis of alpha-conotoxin MII. Biopolymers 2009,92 (1), 23-34. 
16. Guy, C. A.; Fields, G. B., Trifluoroacetic acid cleavage and deprotection of resin-bound peptides 
following synthesis by Fmoc chemistry. Methods Enzymol 1997,289, 67-83. 
17. Fields, G. B., Methods for removing the Fmoc group. Methods Mol Biol 1994,35, 17-27. 
18. Andreu, D.; Albericio, F.; Sole, N. A.; Munson, M. C.; Ferrer, M.; Barany, G., Formation of 





19. Chen, L.; Annis, I.; Barany, G., Disulfide bond formation in peptides. Curr Protoc Protein Sci 
2001,Chapter 18, Unit18 6. 
20. Ariyawansa, T.; Pullman, H.; Amiji, M. M.; Bhavsar, M. M. D. The Development of 
Multifunctional Nanoparticles for Simultaneous Fluorescence Imaging and Gene Delivery. 
http://web.mit.edu/rsi/www/pdfs/papers/2006/2006-thilini.pdf. 
21. James, A. E.; Driskell, J. D., Monitoring gold nanoparticle conjugation and analysis of 
biomolecular binding with nanoparticle tracking analysis (NTA) and dynamic light scattering 
(DLS). The Analyst 2013,138 (4), 1212-8. 
22. Wang, X.; Zhou, L.; Ma, Y.; Li, X.; Gu, H., Control of aggregate size of polyethyleneimine-
coated magnetic nanoparticles for magnetofection. Nano Research 2010,2 (5), 365-372. 
23. Elbakry, A.; Zaky, A.; Liebl, R.; Rachel, R.; Goepferich, A.; Breunig, M., Layer-by-layer 
assembled gold nanoparticles for siRNA delivery. Nano Lett 2009,9 (5), 2059-64. 
24. Gittins, D. I.; Caruso, F., Tailoring the Polyelectrolyte Coating of Metal Nanoparticles. The 
Journal of Physical Chemistry B 2001,105 (29), 6846-6852. 
25. Schneider, G.; Decher, G., Functional core/shell nanoparticles via layer-by-layer assembly. 
investigation of the experimental parameters for controlling particle aggregation and for 
enhancing dispersion stability. Langmuir 2008,24 (5), 1778-89. 
26. Rasband, W. Image J, National Institutes of Health: 2016. 
27. Haiss, W.; Thanh, N. T. K.; Aveyard, J.; Fernig, D. G., Determination of size and concentration 
of gold nanoparticles from UV-vis spectra. Analytical chemistry 2007,79 (11), 4215-4221. 
28. Thermo Fisher Scientific Inc. RNA quantitation is an important and necessary step prior to most 
RNA analysis methods. http://www.webcitation.org/6kdWpl2gs. 
29. Chithrani, B. D.; Ghazani, A. A.; Chan, W. C., Determining the size and shape dependence of 
gold nanoparticle uptake into mammalian cells. Nano Lett 2006,6 (4), 662-8. 
30. Kanaras, A. G.; Wang, Z.; Hussain, I.; Brust, M.; Cosstick, R.; Bates, A. D., SiteSpecific 
Ligation of DNAModified Gold Nanoparticles Activated by the Restriction Enzyme StyI. Small 
2007,3 (1), 67-70. 
31. Lee, J. S.; Green, J. J.; Love, K. T.; Sunshine, J.; Langer, R.; Anderson, D. G., Gold, poly(beta-
amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009,9 (6), 2402-6. 
32. Chesebro, B.; Buller, R.; Portis, J.; Wehrly, K., Failure of human immunodeficiency virus entry 
and infection in CD4-positive human brain and skin cells. Journal of  Virology 1990,64 (1), 215-
21. 
33. Chesebro, B.; Wehrly, K., Development of a sensitive quantitative focal assay for human 
immunodeficiency virus infectivity. Journal of  Virology 1988,62 (10), 3779-88. 
 
